Table 2 Univariate correlations between biomarker levels (baseline and percentage change from baseline to week 2 and week 24) and change from baseline to week 24 in disease activity (BASDAI) and the inflammation detected by MRI (MRI activity score) in patients with ankylosing spondylitis who received infliximab 5 mg/kg (n = 201) or placebo (n = 78)

Biomarker	Change in MRI activity score		Change in BASDAI
Biomarker	Placebo	Infliximab	Placebo	Infliximab
Baseline
IL-6	−0.158	−0.205***	0.062	−0.258***
VEGF	0.067	−0.074	0.140	−0.079
CRP	−0.047	−0.291***	0.169	−0.322***
Percentage change from baseline to week 2
IL-6	0.080	0.260***	0.066	0.297***
VEGF	0.110	0.243***	0.105	0.260***
CRP	0.006	0.296***	−0.017	0.347***
Percentage change from baseline to week 24
IL-6	−0.086	0.215**	0.178	0.340***
VEGF	−0.101	0.170*	0.148	0.330***
CRP	−0.090	0.243***	0.147	0.414***

*p<0.05.
**p⩽0.01.
***p⩽0.001.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; IL-6, interleukin-6; MRI, magnetic resonance imaging, VEGF, vascular endothelial growth factor.